Danaher Corporation (DHR) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 29, 2024; comparisons are with the three months ended March 31, 2023, unless noted. Danaher reports Biotechnology, Life Sciences and Diagnostics. Veralto, separated in September 2023, is reported as discontinued operations, affecting year-over-year comparisons.
Financial performance
| Metric | Q1 2024 | Prior-year period |
|---|---|---|
| Sales | $5.796 billion | $5.949 billion |
| Gross profit / margin | $3.487 billion / 60.2% | $3.662 billion / 61.6% |
| Operating profit / margin | $1.312 billion / 22.6% | $1.517 billion / 25.5% |
| Continuing-operations net earnings | $1.088 billion | $1.240 billion |
| Diluted EPS from continuing operations | $1.45 | $1.65 |
| Operating cash flow | $1.739 billion | $1.806 billion from continuing operations |
| Capital expenditures | $291 million | $266 million |
Total sales declined 2.5%; core sales, excluding acquisitions and currency translation, declined 4.0%. Acquisitions added 2.0% to reported sales and currency translation reduced them by 0.5%, according to management. The effective tax rate was 14.4%, versus 18.6%.
At March 29, 2024, cash and equivalents were $7.031 billion. Total debt was $18.163 billion, including $1.746 billion current and $16.417 billion long-term. Danaher reported compliance with all debt covenants. On April 2, it repaid €900 million of notes at maturity using cash distributions received from Veralto before the separation.
Segment results and material changes
- Biotechnology: Sales fell 18.0% to $1.524 billion; core sales fell 17.0%. Operating margin declined to 21.3% from 32.0%. Bioprocessing weakness reflected reduced customer inventory and tighter funding conditions; discovery and medical sales also declined.
- Life Sciences: Sales rose 2.0% to $1.745 billion, primarily due to acquisitions, while core sales fell 3.0%. Operating margin declined to 13.5% from 18.8%, affected by acquired-business dilution, lower core sales and an acquisition-related inventory charge.
- Diagnostics: Sales rose 6.5% to $2.527 billion; core sales grew 7.5%, led by molecular diagnostics and North America. Operating margin increased to 32.8% from 28.5%.
Consolidated operating margin decreased 290 basis points. Management attributed the decline to lower core sales, product mix and reduced cost-structure leverage (170 basis points), acquired-business dilution (80 basis points), and a $25 million Abcam acquisition-related inventory fair-value charge (40 basis points). The charge also weighed on gross margin.
Net earnings for Q1 2023 included $210 million from discontinued operations; Q1 2024 had none. Accordingly, total net earnings declined to $1.088 billion from $1.450 billion, in addition to the decline in continuing-operations earnings.
Cash, outlook and risks
- Operating cash flow from continuing operations declined $67 million, or 4%, year over year. Cash from operations, investing and financing was $1.739 billion, negative $321 million and negative $133 million, respectively. Cash ended the quarter at $7.031 billion, up from $5.864 billion at year-end.
- Management expects 2024 effective tax rate of approximately 17.5% for the remainder of the year, subject to earnings mix, stock-based compensation tax benefits, audits and other discrete items.
- Management expects bioprocessing core revenue to decline for full-year 2024, with gradual year-over-year demand improvement through the year; reduced demand, including customer inventory reductions, is expected to continue into Q2. The filing provides no overall full-year revenue or earnings guidance.
- Management said high-growth-market sales fell 12% year over year, with high-teens core revenue declines in China. Biotechnology weakness was linked to lower funding and activity levels; currency changes also affect reported results.
- Other risks highlighted include competition, regulation, product and technology development, acquisitions and integration, foreign exchange, debt, cybersecurity and supply-chain disruption. The IRS and other tax authorities continue examinations; Danaher noted the IRS could propose similar self-insurance tax adjustments for periods after 2018, while management believes its tax positions comply with applicable law.
- Foreign currency translation losses of $948 million contributed to a $996 million other comprehensive loss and comprehensive income of just $92 million. These translation effects were recorded in equity, not as a comparable reduction to net earnings.
Key facts for investors to verify
- Whether Biotechnology and China demand stabilize as management anticipates, and whether bioprocessing improves gradually during 2024.
- How Abcam integration, acquired-business dilution and intangible amortization affect margins and earnings in subsequent quarters.
- Whether Diagnostics growth persists and offsets weakness in Biotechnology and parts of Life Sciences.
- Progress against the approximately 17.5% remainder-of-year tax-rate expectation and the outcome of ongoing tax examinations.
- Debt maturities, liquidity and currency exposure, including the effect of exchange-rate movements on sales and comprehensive income.